retatrutide study results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial retatrutide phase 3 trial results

Bellwether trials in mid-2026 will likely accelerate settlement discussions

Those working with tirzepatide reconstitution should follow established protocols to ensure consistent potency and predictable effects

These serious side effects are rare but require immediate medical attention regardless of whether you are using drops or injections

This once daily 3.0 mg subcutaneous injection demonstrated meaningful weight losses in clinical trials with optimal results occurring when combined with reduced calorie diet and increased physical activity

Under the Medicare GLP-1 Bridge, eligible Medicare Part D beneficiaries will have a $50 copay per monthly supply of an eligible GLP-1 drug, they added